U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07035561) titled 'Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis' on June 16.
Brief Summary: Hypersensitivity pneumonitis (HP) presents with a highly variable clinical course, and Traditional treatment involves systemic corticosteroids in conjunction with strict avoidance of the offending antigen. However, a subset of patients with progressive disease remains unresponsive to conventional therapies. The objective of this study is to evaluate the therapeutic potential of Rituximab in individuals with refractory hypersensitivity pneumonitis who did not respond to conventional immunosuppressive therapy and antigen avo...